80 related articles for article (PubMed ID: 3781476)
1. Evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma.
Jungmann E; Schwedes U; Althoff PH; Rosak C; Schöffling K
Horm Metab Res; 1986 Oct; 18(10):704-5. PubMed ID: 3781476
[TBL] [Abstract][Full Text] [Related]
2. Endogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronism.
Jungmann E; Althoff PH; Rosak C; Schwedes U; Schöffling K
Horm Metab Res; 1986 Feb; 18(2):138-40. PubMed ID: 3699687
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy.
Jungmann E; Haak T; Althoff PH; Fassbinder W; Schöffling K
Arzneimittelforschung; 1988 Feb; 38(2):296-300. PubMed ID: 3285838
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.
Carey RM; Thorner MO; Ortt EM
J Clin Invest; 1980 Jul; 66(1):10-8. PubMed ID: 7400305
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic modulation of aldosterone secretion: effect of sodium balance and postural changes.
García-Robles R; Ruilope L; Mancheño E; Hurtado A; Alcázar JM; Varela C; de la Calle H; Rodicio JL; Sancho J
Rev Esp Fisiol; 1984 Mar; 40(1):63-8. PubMed ID: 6087430
[TBL] [Abstract][Full Text] [Related]
7. Serum aldosterone response to metoclopramide in normal subjects and acromegalic patients.
Zacharieva S; Stoeva I; Matrozov P; Andonova K
Exp Clin Endocrinol; 1990 Aug; 95(3):331-8. PubMed ID: 2245821
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic control of aldosterone secretion in hypertensive patients chronically treated with an angiotensin converting enzyme inhibitor.
Waeber B; Nussberger J; Schaller MD; Gomez HJ; Brunner HR
Horm Metab Res; 1986 Jan; 18(1):60-3. PubMed ID: 3005150
[TBL] [Abstract][Full Text] [Related]
9. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
[TBL] [Abstract][Full Text] [Related]
10. [Dopaminergic regulation of hormone secretion of the pituitary gland and the adrenal gland].
Jungmann E; Böttger B; Magnet W; Schulz F; Schwedes U; Althoff PH; Schöffling K
Med Welt; 1983 Feb; 34(7):216-9. PubMed ID: 6835089
[No Abstract] [Full Text] [Related]
11. A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: differences in dopaminergic regulation of PRL and aldosterone secretion.
Demura R; Naruse M; Isawa M; Onoda N; Naruse K; Yamakado M; Demura H
Endocrinol Jpn; 1992 Apr; 39(2):169-76. PubMed ID: 1396349
[TBL] [Abstract][Full Text] [Related]
12. Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.
Carey RM; Thorner MO; Ortt EM
J Clin Invest; 1979 Apr; 63(4):727-35. PubMed ID: 438333
[TBL] [Abstract][Full Text] [Related]
13. Dopamine control of aldosterone secretion in end-stage renal failure.
García-Robles R; Ruilope L; Tovar J; de Villa LF; Miranda B; Prieto C; Parada J; Sancho J; Rodicio JL
Rev Esp Fisiol; 1986 Jun; 42(2):257-63. PubMed ID: 3092288
[TBL] [Abstract][Full Text] [Related]
14. [Lack of effect of aging on dopaminergic inhibition of aldosterone and prolactin increase].
Preis P; Luger A; Templ H; Tragl HK; Geyer G
Z Gerontol; 1985; 18(4):241-3. PubMed ID: 3901563
[TBL] [Abstract][Full Text] [Related]
15. Plasma aldosterone response to metoclopramide is unmodified by hyperprolactinemia.
Serri O
Horm Res; 1987; 27(1):36-41. PubMed ID: 3623428
[TBL] [Abstract][Full Text] [Related]
16. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
Fine SA; Frohman LA
J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
[TBL] [Abstract][Full Text] [Related]
17. Defective dopaminergic regulation of prolactin secretion in patients with hyperprolactinemia.
Serri O; Beauregard H; Somma M; Comtois R; Jilwan N; Hardy J
Clin Invest Med; 1988 Dec; 11(6):387-91. PubMed ID: 3229037
[TBL] [Abstract][Full Text] [Related]
18. Lack of direct effect of dopamine on aldosterone secretion in vivo.
Lun S; Espiner EA; Nicholls MG; Hart DS
Endocrinology; 1983 Jan; 112(1):60-3. PubMed ID: 6847834
[TBL] [Abstract][Full Text] [Related]
19. Dopamine control of prolactin secretion in multiple endocrine neoplasia type I.
Dornan J; O'Leary JG; Farid NR
Clin Invest Med; 1984; 7(3):161-4. PubMed ID: 6151431
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic modulation of aldosterone secretion in the normal menstrual cycle.
Garcia-Robles R; Ruilope LM; Tovar J; de Pablos P; Parada J; Hurtado A; Miranda B; Fernandez Vazquez G; Rodicio JL; Sancho J
J Clin Hypertens; 1987 Dec; 3(4):470-8. PubMed ID: 3134515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
